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Breast cancerOften considered an ‘‘indolent’’ disease for which a treatment de-escalation is advocated, ductal carci-
noma in situ (DCIS) of the breast has been recently shown to be associated with a signiﬁcant increase
in long-term mortality in case of invasive local recurrence (LR). The publication of data from four ran-
domised trials did not prevent the continuation of the debates about the pros and cons of postoperative
radiation therapy (PORT) for optimal DCIS management. Actually only partial answers regarding the
impact of PORT on local control had been brought by these randomised trials among others due to differ-
ences in pathological assessment among these controlled studies. A biologically heterogeneous disease,
DCIS is characterised by a large variation in clinical behaviour, which hampers the identiﬁcation of those
patients for whom PORT might be considered as an overtreatment. At the light of the most recent biolog-
ical and clinical studies, this review tries to identify accurately the LR risks associated with both tumour-
and patient-related factors and to analyse the treatment-related parameters impacting signiﬁcantly on
the patient outcome.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 112 (2014) 1–8 This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).A heterogeneous disease, ductal carcinoma in situ (DCIS) of the
breast is nowadays considered as an important public health issue.
With the development of vast breast screening programmes, it rep-
resents currently up to 20% of newly diagnosed breast cancers (BC)
[1,2]. Although not all DCIS progress to invasive carcinoma, this
histologic pattern has been shown to represent a late stage of cell
deregulation, activating the mammary cancerization processes.
Indeed, in more than 50% of even low-grade DCIS, an invasive can-
cer occurs in the breast after up to 30 years [3]. Progression to
invasive disease is actually the main challenge to DCIS manage-
ment [4]. A true local recurrence may be difﬁcult to differentiate
from a ‘‘new primary’’, partly due to frequent discontinuity growth
of DCIS. In any case, the invasive local recurrence signiﬁcantly
increases long-term mortality [5–8]. This is in sharp contrast with
the current trend to consider DCIS as an ‘‘indolent’’ disease and
subsequently advocates the application of treatment de-escalation
policies. Thus, the objective of this review article is to propose a
critical appraisal of the strategies currently developed to assess
the risk level in individual patients. We also highlight new current
concepts to optimise DCIS treatment and enhance its therapeutic
indices.Historical perspectives
Until the 80s, mastectomy was the reference treatment for DCIS
patients, with an approximate 98% rate of local control [9]. On the
basis of not only the disease extension and/or multi-centricity, but
also in consideration of the patient’s preferences, mastectomy con-
tinues to be performed after 2000 in at least one third of DCIS cases
[2,10,11]. In a 2003–2004 French survey registering 1289 women
with pure DCIS, 31% of the patients underwent mastectomy (50%
in women under 40) [12]. In a retrospective study from Wisconsin,
40.2% of 1676 patients treated between 1995 and 2010 underwent
mastectomy (4.8% bilateral) [13]. An identical rate was found
among 2037 patients treated in Houston from 1996 to 2009 [14],
and even more in some studies from the Netherlands [15,16].
With the increasing occurrence of very small, radiologically
detected subclinical lesions, several teams started considering, in
the nineties, most DCIS as a possibly ‘‘indolent disease’’ and
claimed that lumpectomy alone could be the treatment of choice
in patients presenting with small size unifocal DCIS [17–24].
After the turn of the century, a number of reports strongly chal-
lenged this policy, eliciting, after 5 and 10-year median follow-ups,
local recurrence (LR) rates ranging from 17 to 32%, 40–45% of them
having progressed to invasive carcinoma (Table 1) [23–25].
Even in cohorts including only radiologically detected DCIS with
complete excision, 10-year LR rates varied between 19% and 28%,
35% of which being invasive carcinomas [18,22].
Table 1
Results of series with local surgery alone [published after 2010].
Author Ref. Period n FU [months] LR % Invasive LR % CBC %
Guerrieri-Gonzaga (2010) [23] 1999–05 338 66 14.5 43 5
Kerlikowske (2010) [24] 1983–94 1162 98 27.9 52 NR
Rakovitch (2013) [25] 1994–03 1867 120 19.5 51 4.8
LR: local recurrence, CBC: contralateral breast cancer, NR: not reported.
2 Radiotherapy and DCISIn contrast, other institutions, considering DCIS and invasive BC
as a ‘‘continuum’’ along the neoplastic transformation process,
started delivering, after surgical resection, PORT to the whole
breast (WBRT) in almost all DCIS patients, similar to the treatment
paradigm in invasive BC [26,27]. PORT signiﬁcantly reduces LR
rates as shown by the studies listed in Table 2 [14,25,28–32]. In
recent reports, including a large majority of completely excised
small lesions detected by screening, the 7 and 10-year LR rates
went down to less than 5% after 50 Gy WBRT and frequently an
additional 10–16 Gy boost to the primary tumour bed [14,28,29].
In a recent study from Boston including 246 patients no local
recurrence was observed at a 58-month follow-up interval [28].
Yet, opponents to an intensiﬁcation of the local treatment contin-
ued to consider this approach as a possible ‘‘overtreatment’’
[33,34], for a disease characterised by non-obligate progression
to invasive BC.Randomised trials
In the early nineties, four randomised trials were conducted to
clarify the debated role of PORT in DCIS patients. A total of more
than 4000 patients were accrued from 1985 to 1999 [6,7,35–43].
The characteristics and results of these trials, generating data on
large patient populations and long-term observation times, are
summarised in Table 3.
Brieﬂy, three studies compared local excision with -whenever
possible – tumour free margins versus the same surgical procedure
followed by conventional WBRT delivering 50 Gy in 25 fractions,
without a boost [6,7,35–41]. The UK/ANZ DCIS Trial used a 2  2
factorial plan to also assess the effect of tamoxifen, delivered at
the same time [42,43]. These four studies did conﬁrm that PORT
halves the local recurrence (LR) risk after resection alone, with sim-
ilar effects in reducing the risks of subsequent in situ and invasive
LR. Moreover, in the NSABP B-17 and EORTC trials, this beneﬁt was
observed in all subgroups of patients, including ‘‘low risk’’ (e.g.
low-grade lesions smaller than 20 mm in diameter with tumour
free resection margins) [6,7].
However, these studies are characterised by some limitations,
mainly related to the pathological assessment used (i.e. tumour
size measurement, free margin deﬁnition), lack of routine speci-
men radiography and post-operative mammography [35–39].
Interestingly enough, the challenging issue of accurate DCIS
diagnosis was properly addressed by the results of the centralTable 2
Results of series with local surgery and postoperative radiation therapy [published after 2
Author Ref. Period n
Halasz (2011) [28] 2001–07 246
Alvarado (2012) [14] 1996–07 977
Falk (2011) [29] 1993–07 870
Tunon (2011) [30] 1971–01 232
Rakovitch (2013) [25] 1994–03 1895
Vidali (2012) [31] 1985–00 586
Shaitelman (2012) [32] 1980–93 145
LR: local recurrence, CBC: contralateral breast cancer, NR: not reported.
1 Tumour free margins: 5%; involved/unknown margins: 22%.pathology review performed among 73% and 85% of the cases in
NSABP B-17 and EORTC trials, respectively [36,39]. Indeed, in both
studies, 7% and 5% of the lesions were reclassiﬁed as benign disease
(mainly atypical epithelial hyperplasia), and 2% and 3% of them
were actually considered as micro-invasive carcinoma. A very
important point observed in the 15-year update of the EORTC trial
is the clearly unfavourable impact on survival after invasive LR [7].
Similar results were observed in the combined B17 and B24 NSABP
trials [6].
Meta-analysis
In 2010, the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis conﬁrmed the results of two previous sim-
ilar studies published a few years earlier [44], showing a 15.2%
absolute reduction in LR at 10 years when PORT was added to sur-
gical resection only (12.9% versus 28.1%, log rank 2 p < 0.00001).
Moreover, DCIS patients were shown to beneﬁt from the use of
PORT independently of age (especially older than 50), type of
surgery (lumpectomy versus quadrantectomy), tamoxifen use,
diagnosis method (radiological versus clinical), margin status (free,
close or unknown), nuclear grade, presence of comedo-necrosis,
architectural subtype and tumour size (Table 4).
In addition, the impact of PORT on outcome was equivalent in
terms of both invasive and in situ LR: 6.9% versus 15.4%, and
6.5% versus 14.9%, respectively.
Even in a subgroup of 291 cases with low LR risks (namely,
tumour size 6 20 mm, tumour free margins and grade I), RT
reduced the absolute LR rate by 18% (12% versus 30%, 2p = 0.002).
In contrast, the 10-year contralateral BC rates were similar in both
groups: BCS: 5.1% versus BCS + RT: 7.2% (2p = NS).
Risk factors for local recurrences [LR]
We can stratify prognosticators of LR risks into 3 groups,
namely clinical, histopathological and treatment-related [4,45].Clinical factors
Diagnostic modalities and mammographic characteristics
Symptomatic DCIS patients (e.g., lump, skin retraction, sero-
haemorragic nipple discharge) have a higher LR risk than those
for whom the disease was radiologically detected. In the EORTC010].
FU [months] LR % Invasive LR % CBC %
58 0 0 3
62 2.4 NR 4
120 3.6 NR NR
120 10.81 NR NR
120 12.3 48 5.1
136 10 63 6.8
228 17.5 76 15
Table 3
Prospective randomized trials comparing local surgery with or without postoperative radiation therapy: characteristics, local recurrence [LR] and contralateral breast cancer
[CBC] [6,7,35–43].
NSABP B-17 EORTC 10853 SweDCIS UK/ANZ DCIS
Study period 1985–1990 1986–1996 1987–1999 1990–1998
Follow-up 17.25 15.8 8.4 12.7
Included patients 818 1010 1067 1030
no PORT 405 503 533 508
PORT 413 510 534 522
Mammographic detection [%] 80 71 79 NR
Central pathological review [%] 76 85 26 0
Negative margins required yes yes no yes
Margins free [%] 78 83 80 100
RT dose 50 Gy/25 fr 50 Gy/25 fr 50–54 Gy/25–27 fr 50 Gy/25 fr
Boost 10 Gy/5 fr [9% patients] 10 Gy/5 fr [5% patients] – –
No Port Port No Port Port No Port Port No Port Port
Local recurrences
– Total 35 19.8 30 17 27.1 12.1 19.4 7
– Invasive 19.6 10.7 15 9.5 12.3 7.2 9.1 3.3
– In situ 15.4 9 15 7.5 14.8 4.9 9.7 3.8
CBC 7.9 9.3 7 10 5.9 6.5 4.1 3.3
OS 86* 87* 90 88 90 92 97.91 96.21
PORT: post-operative radiation therapy.
1 All trial participants included.
* At 12 year follow-up.
Table 4
10-year impact of PORT in the EBCTCG 2010 meta-analysis: local recurrence rates in %
[44].
Local resection Local resection + PORT 2p
Age
<50 y 29.1 18.5 0.007
P50 y 27.8 10.8 <0.00001
Surgery type
Local excision 27 12.5 <0.00001
Sector excision 30.4 13.7 <0.00001
Tamoxifen
No 28.8 13.2 <0.00001
Yes 18.3 9.3 0.002
Margin status
Negative 26 12 <0.00001
Positive 43.8 24.2 4E-05
Focality
Unifocal 28.5 11.2 <0.00001
Multifocal 42.2 17.3 <0.00001
Histological grade
Low 21.7 9.5 <0.00001
Intermediate 24.8 16.3 0.01
High 32.2 17.4 0.0005
Comedonecrosis
Present 36.5 16.6 <0.00001
Absent 25.5 12 0.0003
Tumour size [pT]
1–20 mm 28.9 13.1 <0.00001
21–50 mm 39 13 0.0001
PORT = post operative radiation therapy.
Table 5
Local recurrence [LR] rates according to age after local excision + PORT.
Study Ref. Age FU %LR
NSABP B-17 [35,47] <49 15
50–69 90 10
>70 9
EORTC 10583 [38,39] <40 120 35.4
>40 19.5
SWE-DCIS [40,41] <50 20,5
50–57 96 10.3
P58 8.9
French Study [20] <40 32
40–59 84 13
>60 8
International Collaborative Group [48] <40 18
40–49 120 15
50–59 8
P60 5
Milan-EIO2 [23] 635 43
36–40 72 23
41–50 12
>50 9
Houston [14] <40 6.4
40–70 60 2
>70 2.6
William Baumont [49] <45 228 24
>45 8
Multi-centric Italian study [31] 640 120 31.3
>40 9
Florence University [50] 650 92 15
>50 4.3
Ontario [25] <45 120 251
>45 23
122
10
1 Additional boost.
2 Part of the patients treated without PORT.
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symptoms compared to radiologically detected lesions (p = 0.014),
after both local excision (27% versus 16%) and local excision fol-
lowed by PORT (17% versus 11%) [7]. In the SweDCIS trial, a
detailed analysis of micro-calciﬁcation subtypes showed that
‘‘crushed stone and casting-type’’ was associated with a higher his-
topathological grade and more extensive disease. The relative risk
of LR was 2.1 (95% CI: 0.92–4.80) for the casting-type [46].Age
Like for inﬁltrating BC, young age (under 40 or 50) is known to
be associated with an increase LR risk, as conﬁrmed by the retro-
spective studies and randomised trials (Table 5) [14,20,23,25,31,35,38–41,47–50]. The reasons for signiﬁcant higher LR rates
in young women remain somewhat uncertain, in the absence of a
clear impact of both histopathological factors (high grade, multi-
centricity, margin status) and treatment modalities (possibly less
extensive surgery in order to ensure a better cosmetic result).
4 Radiotherapy and DCISThese results are used to justify the choice made by many insti-
tutions in favour of a more ‘‘aggressive’’ approach in young women,
including a higher mastectomy rate and a more frequent use of a
boost after WBRT in order to improve local control [51].
Interestingly, the risk reducing effect of PORT depending on age
is also worth revisiting. In the Swedish Trial, Holmberg et al.
showed that the magnitude of this effect might be less marked in
women <50 years than in patients above 60 years of age [41]. There
are few data on LR rates in the ageing population. In the French
and International studies [20,48], the LR rates in women over
60 years were 8% and 5% after local excision + PORT, with
84- and 120-month follow-ups, respectively. In NSABP B-17 and
Houston series, the rates in women over 70 were 9% and 2%, with
90- and 60-month follow-ups respectively [14,35,47]. A retrospec-
tive analysis of SEER data including 3409 women over 66 treated
by BCS for DCIS between 1992 and 1999 [52] showed that
PORT lowered local recurrence risk with a HR = 0.32 (95% CI:
0.24–0.44). For high-risk patients (tumour larger than 2.5 cm, com-
edo-histology and/or high grade), the 5-year event risk was 13.6%
without RT versus 3.8% with RT (p < 0.001). For low-risk patients,
the same respective rates were 8.2% versus 1% (p < 0.001).Histopathological factors
Margins
In two large multicentric series in which the margin status was
retrospectively analysed [20,53], LR rates at 7 and 10 years were
shown to reach 9% and 25%, respectively, depending upon the
surgical margin status (free margins versus incomplete resection).
This outcome pattern was also found in the results retrieved from
the randomised trials [36,39]. Silverstein et al. suggested the
quality of the excision as the most important factor inﬂuencing
local outcome. They selected three margin status (<1, 1–9 and
10 mm or more) as an important issue for the stratiﬁcation of
patients into 3 levels of LR risk after local resection with or without
PORT [54–56].
However, the exact margin status is known to be either very dif-
ﬁcult to deﬁne with precision [57], or to be even often unspeciﬁed,
both in retrospective series as in randomised trials. Furthermore,
the deﬁnition of a ‘‘negative margin’’ varies widely from one study
to another (1, 2, 3, 5 or 10 mm, or ‘‘untouched ink’’). At the 2000
Philadelphia Conference, no consensus could be reached between
pathologists on the deﬁnition of the ‘‘optimal free margin’’ [58].
As a matter of fact, many reports on ‘‘margin status versus local
recurrence risk’’ are retrospective and lack a standardised assess-
ment of margins in terms of orientation, inking and specimen
sectioning. Moreover, the rate of ‘‘close’’ or ‘‘uncertain’’ margins
widely varies among the series. However, a clear difference in LR
rates was observed in some series between ‘‘negative’’ and ‘‘posi-
tive’’ margins, with 9% versus 24% and 10% versus 25% in the Inter-
national Collaborative Study [48] and the multi-centric French
series [20], respectively. The EORTC trial, with central pathology
review for most of the patients, showed very similar results [39].
Finally, in several cases of ‘‘minimal’’ or ‘‘uncertain’’ free margins,
and ‘‘focally involved’’ margins, a 10–16 Gy boost was used in
order to (empirically) reduce the LR risk. The latest report from
the Curie Institute seems to conﬁrm the interest of such an
approach [59]. Indeed, among 147 women with DCIS treated by
breast-conserving surgery who had either close margins (<2 mm)
or focally/minimally involved margins, a 16 Gy minimal dose boost
gave a 9.3% LR rate with 89-month FU.
In the Dunne and al meta-analysis of 4660 patients treated with
local excision followed by PORT including 22 studies with data on
resection margins, the LR odd-ratios were 2.56 (p < 0.05), 2.89
(p < 0.05) and 1.51 (p = NS) for a minimally negative margin with
no tumour cells at the inked margin, P1 mm margin, andP2 mm margin, respectively, compared to a minimal margin of
5 mm [60].
On the other hand, surgical margins exceeding 5 mm were not
clearly associated with lower rates of LR. However, it is impossible
to effect of extrapolating this latter approach, maximising the
extent of the free margins, to ‘‘high-risk’’ subgroups, such as in
women under 40, in multifocal disease or to patients without
PORT. Moreover, another meta-analysis by Wang [61] including
7564 patients treated by local excision ± RT, showed a progressive
reduction of LR with progressive increments in margin width of 2,
5 and 10 mm.
Actually, surgical margin analyses are often obfuscated by the
frequent practice of ‘‘re-excisions’’, sometimes difﬁcult to trace in
the publications. Finally, a correlation between total excised vol-
ume and tumour free-margin status seems to emerge from recent
reports on histologic predictors of recurrences [62,63].
Tumour size
Many factors hamper the identiﬁcation of the exact extension of
a DCIS lesion, including uncertainties linked to the exact relevance
of mammographic micro-calciﬁcations, and discontinuous growth
patterns, especially in low-grade lesions [57,64]. These features
certainly often account for the underestimation of the exact DCIS
dimension. In addition, the literature is characterised by a wide
variation in assessing, recording and reporting DCIS size in individ-
uals. While in the EORTC trial, only 25% of the lesions were mea-
surable with precision, with clear dimensions expressed in mm
[37,38], the 2003–2004 French survey documented the disease size
in 97% of the patients: lesions <10 mm, 10–20 mm and >20 mm
were found in 41%, 27% and 32% of the cases, respectively [12].
In general the correlation between DCIS size and LR still remains
poorly documented. However, a recent report from Houston [14]
showed a signiﬁcant inﬂuence of tumour size on LR, with 5-year
LR rates of 5.6% versus 2.2% (p = 0.018) for lesions over and under
15 mm, respectively.
Nuclear grade
Nuclear grade was analysed in many cohorts of patients treated
or not with PORT, and it is well documented that about one third of
DCIS displays complex histologic patterns, including the presence
of varying nuclear grades within the same lesion.
Therefore nuclear grade is nowadays included in the panel of
risk factors integrated into most LR nomograms [25,65–68] and
several other studies analysing LR risk factors [7,25,68].
The Van Nuys team reported that in 583 patients, treated by
local excision with or without RT, the 12-year LR rates increased
with the nuclear grade (13%, 23% and 45% for low, intermediate
and high grade DCIS, respectively) [34].
In the EORTC trial, the 10-year LR rates were, in the surgery
alone group, 18%, 34% and 35% for grade I, II and III lesions, respec-
tively. These rates went down to 9%, 23% and 19% when PORT was
added to surgery [39].
Nevertheless the impact of grade on outcome has also to be
weighted in the function of the time elapsed after treatment: in
a large multi-centric study, Solin demonstrated that LR rates varied
widely between low and high-grade DCIS during the ﬁrst 7–8 years
of follow-up, while at 10 years, these rates were almost identical.
Molecular proﬁling
Compared with invasive breast cancer, the study of biomarkers
in DCIS remains hardly documented. A wide-nested case–control
study in a population-based cohort of 1152 women treated in
San Francisco area from 1983 to 1994 by lumpectomy alone, ana-
lysed several clinical and immunohistochemical local recurrence
risk factors [24]. The eight-year risk of invasive LR was statistically
signiﬁcantly higher (p = 0.018) for women with DCIS that were
B. Cutuli et al. / Radiotherapy and Oncology 112 (2014) 1–8 5p16, COX-2 and Ki-67 triple positive, whereas the 8-year risk of
in situ LR was higher for DCIS with ER-, ERB2+ or p16+, COX-2-
and Ki67+. These ﬁndings suggest that probably different pathways
predict for progression into in situ or invasive LR after primary
treatment for DCIS. In a review published in 2011, Lari et al., ana-
lysing 6252 patients, found no signiﬁcant correlation between
treatment outcome and the expression of various biologic factors
at the time of diagnosis, including steroid receptors, proliferation
markers, growth factors families receptors, cell cycle regulation/
apoptotic markers, COX-2 expression, and extracellular matrix-
related proteins [69]. In an attempt to identify biologic factors with
predictive values similar to those documented for invasive
carcinoma, a number of biomarkers are currently under intensive
investigation, e.g., biological proﬁles similar to those of invasive
breast cancer [70], chromosome-wide comparative genomic
hybridisation [71,72], expression at oligo-nucleotide probes [73],
proteomics analyses [74], growth, angiogenic and lymphangiogen-
ic factors assays [75], and matrix-metalloproteinases (MMPs) asso-
ciated to their tissue inhibitors (TIMPs) [76]. More recently, Solin
used a ‘‘DCIS score’’ derivated from the ‘‘Oncotype DX’’ test (used
for invasive BC) among 327 patients included in the ECOG Trial
[77]. This test was based on proliferation (5), hormonal receptors
(1) and reference (5) group genes. In this very selected population,
low, intermediate and high-risk DCIS score predicted a 10.6%,
26.7% and 25.9% 10-year rate of local recurrences respectively.Treatment-related factors
Boost after WBI
For invasive BC, a large EORTC randomised trial showed the sig-
niﬁcant impact of a 16-Gy boost in LR reduction, regardless of age,
but with a maximum impact in women under 40 [78]. For DCIS, a
retrospective multicentric study showed in women under 45 with
a 72-month follow-up a 54% LR rate after BCS only, 28% after
BCS + WBI, and 16% for WBI with additional boost, respectively
[51]. In other retrospective reports, the boost rates were extremely
heterogeneous, especially with various doses and techniques. In a
study from Ontario, there was no boost impact in 561 out of
1895 patients treated from 1994 to 2003 [79], with a similar 12%
LR rate at 10 years. In a study from Florence [80], no positive
impact of boost was found, but with signiﬁcantly unfavourable fac-
tors (margins < 4 mm and high VNPI) in patients treated with
boost. On the contrary, another two recent studies from Boston
and Houston showed very low LR rates by systematic boost use
(Table 2) [14,28]. Two randomised trials are still ongoing in order
to answer this question.
Tamoxifen (TAM)
Two randomised trials analysed the impact of TAM in patients
treated for DCIS by BCS with or without PORT. In the NSABP
B-24, 1799 patients were randomised after BCS + PORT for receiv-
ing or not 5 years of tamoxifen (10 mg twice a day). In the 2011
updated analysis [6], TAM reduced LR rate from 16.6% to 13.2%.
However, in 76% of the patients with negative margins, an identical
7.5% LR rate was observed in both arms, with related very similar
2.3% and 2.7% BC speciﬁc mortality rates.
In the UK/ANZ DCIS Trial, a factorial 2  2 plan was made to
analyse both TAM and PORT impacts [42]. Thus, there were 4
subgroups for a total of 1694 screened patients (over 50). In the
subgroup treated by BCS + PORT, the LR rates were almost identical
in TAM and placebo arms (20 versus 22) [43]. Thus, in both studies,
for patients treated by BCS + PORT, TAM did not add a special ben-
eﬁt. However, there were no data on ER status, and it is doubtful
whether a speciﬁc subgroup might beneﬁt from TAM, as suggested
by some retrospective studies. Moreover, it is always necessary to
assess the potential toxicity of TAM (e.g. endometrial cancer,thrombo-embolic accidents), especially in women over 50. There-
fore, we suggest to consider the conclusion of the meta-analysis
on the use of TAM in DCIS with great caution [81].
Local recurrences [LR]: from diagnosis to treatment and ﬁnal
prognosis
After long-time follow-up, the occurrence of a LR is found to
affect negatively the ultimate prognosis of DCIS patients, especially
when the disease progresses to invasive carcinoma [6–8]. Median
times to LR are estimated to be 36–48 and 48–60 months after
local surgery, without and with PORT, respectively [17,20,48].
The LR occurrence is earlier in high-grade DCIS [82].
LR can be diagnosed by clinical symptoms, but in many cases by
mammographic new foci of microcalciﬁcations, and/or the occur-
rence of an architectural distortion [83]. The relative proportion
of these diagnosis modalities remains unknown.
The fact that about 75% of LR occurs at the lumpectomy site or
inside the index quadrant conﬁrms the validity of the hypothesis of
residual cancer cells after an incomplete eradication with local
treatment, even in the presence of free margins [83]. In almost
all series, about 50% of LR is again of DCIS type [4,9,31]. In such
cases, the long-term prognosis is excellent, both in retrospective
studies [8] and in randomised trials [7].
After local surgery alone, about 50% of the patients is eligible for
a salvage treatment that again consists of a breast-conserving
approach, including local surgery and PORT [7,8]. After local sur-
gery and PORT, salvage mastectomy is generally performed [in
80–90% of the cases] [8,84,85].
However, about 50% of the LR are micro-invasive (below 2 mm)
or invasive. In such cases, axillary nodal involvement is not uncom-
mon (e.g., 26% in the multicentric French series) and the long-term
metastatic risk reaches 15%, as conﬁrmed in several studies
[7,8,85]. Indeed, among 1003 patients included in the International
Collaborative Group study (all detected by mammograms) and
treated by local surgery and PORT, 56 (6.2%) experienced progres-
sion to invasive carcinoma, and 8 of them (14.3%) developed dis-
tant metastases [53]. In the French study, among 403 and 812
patients treated by local surgery alone and by local surgery with
PORT, 113 (9%) invasive LR occurred with 16 subsequent meta-
static evolutions (14.2%) [8]. Moreover, a higher relative risk (RR)
of death due to BC after the occurrence of an invasive LR was
observed in several studies [5–7]. Wapnir et al., combining the
long-term results of the NSABP B-17 and B-24 trials, found a 1.75
RR for BC-related deaths in patients with invasive LR [6]. Likewise,
in the EORTC trial analysis reporting results at a 15-year median
follow-up, BC-related speciﬁc survival rates decreased from 95%
to 60% in patients experiencing an invasive LR, with a 5.00 RR for
BC-related deaths [7].
Discussion
DCIS is a biologically and clinically heterogeneous disease [1,4],
with a natural history inﬂuenced by both tumour- and host-related
factors. Consequently, DCIS treatment after BCS still remains
controversial [86], with the feeling that a fraction of the DCIS
population might be over-treated. These uncertainties were
partly generated by several methodological biases in many non-
randomised studies, including the more frequent delivery of PORT
for younger and higher risk patients and the addition of hormonal
therapy as a supplementary confounding factor [5,34,45,65,68,81].
Up to now, accelerated partial breast irradiation (APBI) has been
considered ‘‘unsuitable’’ for DCIS according to ASTRO selection cri-
teria. However, this position is changing, at least for very small
lesions excised with wide margins. Several studies are still ongoing
on this topic [87], but the follow-up is short.
6 Radiotherapy and DCISSimple ﬁgures illustrate the duality of recent statements on DCIS
management. Based on a Cochrane Database, it can be estimated
that 9 patients have to be treated to prevent one LR [88], but ran-
domised trials have repeatedly shown that PORT was efﬁcient in
all DCIS sub-groups, reducing globally the risk of LR by about 50%
[6,7,41,43]. Moreover, the number needed to treat to prevent one
LR decreases to 6–7 with longer follow up (EBCTCG) [44].
What happens to DCIS patients when treated with local surgery
alone? Literature studies on lumpectomy alone were characterised
by huge variations in selection criteria and treatments [11,54,89–
91]. The prospective ECOG Study ‘‘E 5194’’ showed that the ipsilat-
eral LR rates in 670 patients were correlated to the disease grade:
for lesions of low and intermediate grade with a maximum diam-
eter of 2.5 cm and with surgical margins ofP3 mm, the LR rate at
10 years was 14.5%, compared to 19% for high-grade lesions up to
1 cm of diameter. It is noteworthy to underline that the median age
was 60 years, the median sizes of the lesions in both groups were
only 6 and 5 mm, respectively, and the tumour free resection
margins were P5 mm in 83% and P10 mm in 53% of the cases,
respectively. Moreover, about 30% of the patients received adju-
vant TAM. Despite this very important selection including only
‘‘very low-risk’’ patients, the recurrence risk without PORT
remained high, with 53% of local invasive recurrences [92]. Among
46 LR, 20 (43%) were invasive [77]. DCIS scores (performed subse-
quently in half of the cases) were assessed as intermediate or high
and low in 30% and 70% of the cases, respectively. The correspond-
ing 10-year LR rates were 26% and 10.6% respectively. A similar
study from Boston was closed preliminary after inclusion of 157
of the scheduled 200 patients because of an unexpected high
recurrence risk of 12.5% at 5 years after local surgery alone [91].
Among 19 LR, six (32%) were invasive. On the other hand,
another study including 263 tumours with the same E5194 study
criteria (but with a 55-year median age and 8 mm median tumour
size) showed with additional PORT a 70% reduction in 7-year LR
rates, with only 4.4% and 2% in Cohort 1 and 2, respectively [93].
Many authors state that PORT is not affecting overall survival in
DCIS patients. This was conﬁrmed in four randomised trials and the
EBCTCG meta-analysis [44]. However, even the meta-analysis
remains underpowered for this endpoint. Longer follow-up might
be required, as death due to breast cancer after DCIS is a tertiary
level effect after invasive recurrence and distance metastases.
Interestingly enough the 1991–2001 SEER Database (n: 1103),
showed that the breast cancer-related death rate was signiﬁcantly
higher in patients treated with local surgery alone (2.1%) than in
those receiving PORT (0.4%) despite more unfavourable features
in the PORT group [5].
Moreover, the latest results of EORTC trial showed a dramatic
impact of invasive LR, with only a 60% 15-year survival rate [7].
Similar results were shown in a retrospective multi-centric French
study, with a 16.8% rate of metastases after invasive LR, versus 3.6%
after in situ LR [8]. Many factors interact with the real impact of
PORT on local outcome, including the underlying complex biology
of the disease, broad variations in clinical and pathological features
in individual patients, and, last but not least, a lack of homogeneity
in both surgery and radiotherapy procedures. However, the argu-
ments against omission of PORT are manifold:
 Firstly, sub-group analyses are as yet unable to identify patients
not beneﬁting from PORT in terms of local control. For example,
even the randomised trials were unable to say whether a com-
plete excision could make PORT unnecessary. In addition, the
increase in ipsi-lateral breast events beyond 5 years warrants
caution regarding the apparent indolent outcome of the good-
risk DCIS subsets, such as small-size, low-grade, completely
excised lesions, especially when adjuvant tamoxifen is given
as well. Secondly, a subset of patients could much probably beneﬁt from
boost, but the results in the literature are still discordant. In a
large study from Ontario [94], LR rates are similar in patients
treated by boost (12%) or not (13%), whereas four series suggest
a favourable impact of boost in local control [14,28,80,95].
 Thirdly, it is not because we do not see nowadays any impact on
survival for PORT that it does not exist. The incidence of late
recurrences following treatment of DCIS is real, especially in
patients with low and intermediate grade lesions. Though prob-
ably limited, the long-term mortality impact of these recur-
rences should not be underestimated, as
strongly suggested by the NSABP B17 and B24 trials which dem-
onstrated, after 12 years follow-up, a twofold hazard ratio after
the occurrence of an invasive local recurrence [6].
 Fourthly, the potential cardiac toxicity after whole breast irradi-
ation is extremely low with modern techniques. Indeed, cardio-
toxicity can mainly be associated with nodal irradiation (never
performed in DCIS) and/or older techniques. Two studies, both
with 8-year median follow-up, showed no signiﬁcant differ-
ences in cardiac mortality or morbidity between right- and
left-sided invasive BC and DCIS after PORT [96,97]. Moreover,
a wide study from Houston conﬁrmed a very important cardio-
toxicity reduction according to time, conﬁrming the huge
technical improvement in the last two decades [98]. Similarly,
the risk of second cancer remains very low. In a large study from
Denmark (with about 45% of the women smokers), among 23
627 patients irradiated for all BC stages from 1982 to 2007,
928 (4%) second cancers occurred; 226 were deﬁned as
‘‘RT-associated site’’, including 186 (82%) lung cancers. The spe-
ciﬁc incidence of second cancer after exclusive WBI was not
speciﬁed, but in this subgroup the ‘‘second cancer risk’’ might
well be much less than 1/200 as calculated for the overall pop-
ulation [99].
 Fifthly, TAM after BCS does not compensate for the absence of
PORT, such as clearly shown by UK-ANZ DCIS Trial [43] and
NSABP B-24 Trial in the group with negative margins treated
by BCS and PORT.
 Finally, the ultimate prognosis of patients experiencing a local
recurrence is not good. Indeed, approximately 15% will develop
subsequent metastases [6–8].Conclusions
In DCIS patients, PORT approximately halves LR rates, both
in situ and invasive. The impact of a tumour-bed boost to further
improve local control is being tested in two on-going randomised
trials [100,101]. The value of adjuvant tamoxifen is limited, at
the best [42,43,47,66,82]. Current uncertainties regarding the opti-
mal treatment of DCIS result from persistent inconsistencies across
prospective and observational studies about the predictive value of
risk factors currently used in statistical analyses.
Overall, there remains signiﬁcant uncertainty about determin-
ing a ‘‘low-risk’’ subgroup of patients for which PORT might be
omitted. In the future, molecular proﬁling (Ki 67 and Her2) may
help us to develop more robust assays to predict, in individual
patients, DCIS or invasive carcinoma progression after local exci-
sion only [102]. Currently, ‘‘observational’’ studies in low-grade
DCIS are being set up to provide new information [103].
In view of the existing lack of knowledge on biologic features
and response to treatment, combined with the unfavourable out-
come after occurrence of an invasive local recurrence, a thorough
discussion with the patient on the beneﬁts and the limitations of
each treatment option should be held, emphasising the possible
long-term risks of under-treatment.
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